论文部分内容阅读
为研究α-干扰素(α-IF)对育龄晚期及绝经期前子宫内膜腺-囊型增生(DCHE)患者受体调解(receptor modulating)作用及临床-形态学效应,38例经组织学检查证实为DCHE患者(平均年龄44.9±1.5岁)纳入研究,其中21例接受孕激素联合α-IF治疗(观察组):在子宫镜监视下分段诊刮后的4～15 d,隔日肌注α-IF 100万U,疗程剂量600万U;在α-IF疗程结束后3～5 d给予孕激素治疗。17例在分段诊刮后的18～20 d开始接受孕激素单一治疗(对照组)。在分段诊刮
In order to investigate the effect of α-IF on receptor modulating and clinical-morphological effects in late stage of childbearing and premenopausal women with endometrial glandular cystic hyperplasia (DCHE), 38 cases of histological The study confirmed that patients with DCHE (mean age 44.9 ± 1.5 years) were enrolled in the study, 21 of whom received progestin combined with α-IF (observation group): 4 to 15 days after segmental curettage under hysteroscopy, Note α-IF 1 million U, the dose of 6 million U; in the α-IF after 3 to 5 days to give progesterone treatment. Seventeen patients received the single treatment of progestin (control group) 18 to 20 days after the sub-curettage. In the sub-curettage